Benitec Biopharma (NASDAQ:BNTC) Director Purchases $188,088.32 in Stock

by · The Markets Daily

Benitec Biopharma Limited (NASDAQ:BNTC – Get Free Report) Director Suvretta Capital Management, L bought 16,384 shares of the business’s stock in a transaction dated Friday, December 19th. The shares were bought at an average cost of $11.48 per share, for a total transaction of $188,088.32. Following the transaction, the director owned 9,560,825 shares in the company, valued at approximately $109,758,271. The trade was a 0.17% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Suvretta Capital Management, L also recently made the following trade(s):

  • On Monday, December 22nd, Suvretta Capital Management, L purchased 19,542 shares of Benitec Biopharma stock. The stock was bought at an average price of $12.08 per share, with a total value of $236,067.36.
  • On Thursday, December 18th, Suvretta Capital Management, L acquired 10,215 shares of Benitec Biopharma stock. The shares were purchased at an average price of $11.24 per share, for a total transaction of $114,816.60.
  • On Friday, November 7th, Suvretta Capital Management, L bought 1,481,481 shares of Benitec Biopharma stock. The stock was purchased at an average cost of $13.50 per share, for a total transaction of $19,999,993.50.

Benitec Biopharma Trading Up 0.7%

Benitec Biopharma stock opened at $13.05 on Thursday. Benitec Biopharma Limited has a 12-month low of $9.70 and a 12-month high of $17.15. The firm has a 50-day moving average price of $13.71 and a 200-day moving average price of $13.44. The firm has a market capitalization of $441.87 million, a PE ratio of -10.79 and a beta of 0.20.

Benitec Biopharma (NASDAQ:BNTC – Get Free Report) last posted its quarterly earnings data on Friday, November 14th. The biotechnology company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.13. As a group, sell-side analysts predict that Benitec Biopharma Limited will post -1.48 earnings per share for the current fiscal year.

Institutional Trading of Benitec Biopharma

Hedge funds have recently bought and sold shares of the stock. Infinitum Asset Management LLC boosted its position in Benitec Biopharma by 435.7% during the 1st quarter. Infinitum Asset Management LLC now owns 1,125,000 shares of the biotechnology company’s stock valued at $14,636,000 after acquiring an additional 915,000 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Benitec Biopharma by 2.4% during the 3rd quarter. Vanguard Group Inc. now owns 992,114 shares of the biotechnology company’s stock worth $13,919,000 after purchasing an additional 22,948 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Benitec Biopharma by 77.6% during the 2nd quarter. Geode Capital Management LLC now owns 415,211 shares of the biotechnology company’s stock worth $4,859,000 after purchasing an additional 181,391 shares during the last quarter. Ameriprise Financial Inc. boosted its position in Benitec Biopharma by 40.5% during the third quarter. Ameriprise Financial Inc. now owns 154,414 shares of the biotechnology company’s stock valued at $2,166,000 after purchasing an additional 44,489 shares in the last quarter. Finally, AWM Investment Company Inc. grew its stake in Benitec Biopharma by 35.2% in the first quarter. AWM Investment Company Inc. now owns 137,977 shares of the biotechnology company’s stock valued at $1,795,000 after purchasing an additional 35,950 shares during the last quarter. Hedge funds and other institutional investors own 52.19% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have commented on BNTC. Zacks Research raised Benitec Biopharma from a “strong sell” rating to a “hold” rating in a research report on Friday, November 14th. Oppenheimer restated an “outperform” rating and issued a $29.00 price target (down from $35.00) on shares of Benitec Biopharma in a report on Tuesday, September 16th. Citigroup reaffirmed an “outperform” rating on shares of Benitec Biopharma in a research note on Tuesday, November 4th. Wall Street Zen raised shares of Benitec Biopharma from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. Finally, HC Wainwright set a $32.00 target price on shares of Benitec Biopharma and gave the stock a “buy” rating in a research note on Monday, November 24th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $26.25.

Check Out Our Latest Analysis on Benitec Biopharma

About Benitec Biopharma

(Get Free Report)

Benitec Biopharma Ltd (NASDAQ: BNTC) is a clinical-stage biotechnology company developing gene-silencing therapies for serious human diseases. The company’s proprietary DNA-directed RNA interference (ddRNAi) platform is designed to enable sustained expression of small RNA molecules that specifically target and silence disease-causing genes. By integrating RNAi sequences directly into DNA constructs, ddRNAi aims to provide a long-term therapeutic effect from a single administration.

Benitec’s lead programs include development of ddRNAi candidates for chronic hepatitis B virus infection and for certain ocular conditions.

Read More